FAKTOR OPTIONSSCHEIN - GILEAD SCIENCES | Real-time BOERSE MUENCHEN 04:25:30 2024-06-26 EDT | ||
| 4.6 EUR | +2.06% |
|
| Current month | -21.05% | ||
| 1 month | -17.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 4.6 | +2.06% |
| 24-06-25 | 4.507 | +4.72% |
| 24-06-24 | 4.304 | -3.82% |
| 24-06-21 | 4.475 | -7.27% |
| 24-06-20 | 4.826 | -13.87% |
Real-time BOERSE MUENCHEN
Last update June 26, 2024 at 04:25 am
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | Goldman Sachs |
| WKN | GX4LZU |
| ISIN | DE000GX4LZU8 |
| Date issued | 2021-12-02 |
| Strike | 104.4 $ |
| Maturity | Unlimited |
| Parity | 7.49 : 1 |
| Emission price | 9.86 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.49 € |
|---|---|
| Lowest since issue | 3.29 € |
| Spread | 0.02 € |
| Spread % | 0.43% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.61
USD
Average target price
82.97
USD
Spread / Average Target
+19.19%
- Stock Market
- Certificates
- Certificat
